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Breast cancer is a highly heterogeneous disease representing tumors 
with distinct histology, gene expression patterns, and genetic 
alterations (1–4). Marker analysis revealed the existence of human 
epidermal growth factor receptor 2–positive (HER-2/NEU+) and 
estrogen receptor–positive (ER+) breast tumors as well as triple-
negative tumors (TNTs), which do not express hormone receptors 
or HER-2/NEU (5). Likewise, microarray profiling identified lumi-
nal-A–like, luminal-B–like, HER2/NEU+, and basal-like breast car-
cinomas (2, 6–8). More recently, basal-like breast carcinoma were 
recognized as a subgroup of TNTs that also include metaplastic 
and claudin-low subtypes (9, 10, 11–14). The metaplastic and 
claudin-low TNTs exhibit epithelial-to-mesenchymal transition 
(EMT) and a cancer stem cell expression signature (9, 10, 14, 15). 
Although the basal-like subtype responds to chemotherapy, no 
effective treatment is available for metaplastic and claudin-low 
tumors; metastatic disease is virtually untreatable.
The tumor suppressors breast cancer 1 (Brca1), p53, phosphatase 
and tensin homolog (Pten), and retinoblastoma 1 (RB1) are com-
monly lost in familial and sporadic forms of TNTs (16–19). RB1 
gene rearrangement was reported in approximately 10% of prima-
ry breast carcinomas of undefined subtypes and in approximate-
ly 20%–25% of breast cancer cell lines, including MDA-MB436, 
MDA-MB468, and BT549, which are derived from TNTs (20–27). 
Microarray analysis revealed that RB1 transcripts are downregu-
lated in about 70% of basal-like breast tumors with concomitant 
induction of the CDK4/6 inhibitor p16Ink4a, a target for transcrip-
tional repression by the RB1 protein, pRb (28). Low RB1 gene 
expression and loss of heterozygosity (LOH) at the RB1 locus 
were subsequently identified at high frequency in luminal-B– 
like and basal-like/TNTs (29). In accordance, a recent study has 
demonstrated loss of pRb expression coupled with high expres-
sion of p16Ink4a and p53, presumably a stabilized mutant form, 
in most basal-like/TNTs (30).
pRb regulates cell growth and differentiation by modulating the 
activity of transcription factors such as E2F family members (31, 32). 
Among E2F-responsive genes are factors required for cell cycle pro-
gression and apoptotic cell death (33). Apoptosis downstream of 
pRb is often, but not always, mediated by the tumor suppressor 
p53 (34, 35). Accordingly, pRb and p53 are commonly lost together 
in cancer; various DNA viruses harbor oncoproteins, such as SV40 
large T antigen (SV40 Tag), that transform host cells by sequester-
ing pRb and its relatives p107 and p130 as well as p53 (36, 37).
Much insight into Rb function was gained through analysis of 
mutant mice. Most Rb+/– heterozygote mice die at approximately 11 
months of age with a wasting disease caused by pituitary tumors, 
whereas Rb–/– embryos die at midgestation (38). Rb loss in many tis-
sues leads to ectopic cell proliferation, apoptosis, and incomplete 
differentiation (38). Mammary placodes from Rb–/– embryos devel-
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op normally when transplanted into recipient mammary glands 
(39). In contrast, mammary gland–specific transgenic expression 
of SV40 Tag, which binds the pRb protein family (pRb, p107, and 
p130), p53, and other factors, such as p300/CBP, or of a truncated 
form (T121), which binds the Rb family but not p53, induces mam-
mary tumors (40–42). Thus, the long-term consequences of Rb 
inactivation alone on mammary gland tumorigenicity and breast 
cancer subtypes are yet to be determined.
Here we describe the effects of somatic inactivation of Rb in 
mammary epithelium using a floxed Rb allele and mammary-
specific deleter Cre lines. We found that deletion of Rb in stem/
early progenitor cells led to focal metaplastic lesions with squa-
mous transdifferentiation and progression to form mammary 
tumors with features of luminal-B or basal-like/EMT breast car-
cinomas, with a subset of the latter exhibiting p53 mutations. 
Combined inactivation of Rb and p53 led to a uniform type of 
EMT tumor that was highly aggressive, yet readily inhibited 
upon reintroduction of pRb.
Results
Targeted inactivation of Rb in mammary epithelium via WAP-Cre induces 
lactation defects, but not mammary tumors. Loss of Rb was previously 
modeled by targeted expression of SV40 Tag in the mammary 
gland under control of the whey acidic protein (WAP) promoter. 
This promoter directs gene expression to differentiating mamma-
ry epithelium during the estrous cycle and lobuloalveologenesis 
as well as to parity-identified stem cells during pregnancy (43, 44). 
The WAP-Cre deleter line was crossed with Rbfl mice, which harbor 
a floxed Rb exon 19 allele (45), yielding WAP-Cre:Rbfl/fl mice. In 
many tissues, concurrent inactivation of Rb with p107 or p130 is 
required to induce tumors (46, 47). We therefore also inactivated 
p107, which is coexpressed with Rb in the mammary gland, by 
crossing WAP-Cre:Rbfl/fl mice into a p107–/– background (48–50).
Mammary gland development and lactation proceeded 
apparently normally in young nulliparous and parous 
WAP-Cre:Rbfl/fl:p107–/– females (data not shown). However, 
by 6 months of age, about half of multiparous WAP-Cre: 
Rbfl/fl:p107–/– females exhibited lactation defects, leading to 
impaired development and death of their offspring (Figure 1A). 
Newborns from these WAP-Cre:Rbfl/fl:p107–/– females suck-
led, but contained very little milk in their stomachs, and 
their growth retardation and morbidity could be rescued 
by transferring to foster mothers (data not shown). Consis-
tent with this defect, lobuloalveoli of lactating mammary 
glands from WAP-Cre:Rbfl/fl:p107–/– females were less dense 
compared with those from controls (Figure 1, B and C) and 
contained adipocytes, which are normally absent at late preg-
nancy and lactation, as well as many involuting lobuloalveoli 
(Figure 1, D–F). Whole-mount analysis of 10 mammary glands 
from 1- to 2-year-old nulliparous and multiparous WAP-Cre: 
Rbfl/fl:p107–/– mice failed to detect any microscopic tumors, 
and of more than 40 WAP-Cre:Rbfl/fl:p107–/– females that sur-
vived for up to 2 years, only 1 developed a tumor (solid adeno-
carcinoma; data not shown).
Targeted inactivation of Rb in mammary epithelium via MMTV-
Cre induces squamous metaplasia and acinar hyperplasia. To delete 
Rb during ductal morphogenesis we used a mouse mammary 
tumor virus–Cre (MMTV-Cre) deleter, MMTV-CreNLST (44). 
As with WAP-Cre, ductal morphogenesis, lobuloalveologen-
esis, involution, and lactation proceeded apparently normally 
in MMTV-CreNLST:Rbfl/fl and MMTV-CreNLST:Rbfl/fl:p107–/– females 
(data not shown). However, at 10–14 months of age, mammary 
glands from 16 of 20 multiparous Rb mutant (RbΔfl) females were 
found to contain micronodules (Figure 2, A and B). None of 10 con-
trol mammary glands contained such lesions (Figure 2, C and D). 
Histopathology of nodules from 2 MMTV-Cre:Rbfl/fl:p107–/–, 
4 MMTV-Cre:Rbfl/fl:p107+/–, and 2 MMTV-Cre:Rbfl/fl:p107+/+ mice 
revealed that each represented acinar hyperplasia with keratinizing 
squamous metaplasia (Figure 2E).
The hyperplastic lesions (n = 8) exhibited high levels of apop-
tosis and cell proliferation, as determined by in situ TUNEL 
and immunohistochemistry (IHC) for proliferating cell nuclear 
antigen (PCNA), respectively (Figure 2, F and G). The lesions 
expressed cytokeratin 5 (CK5), a marker of mammary myoepithe-
lium and epidermis, and the epidermis-specific differentiation 
marker CK6 (Figure 2, H and I). Similar results were obtained 
regardless of p107 status. Thus, inactivation of Rb or Rb plus 
p107 via MMTV-CreNLST induced focal lesions characterized by 
hyperplastic growth and apoptosis with transdifferentiation into 
epidermal-like structures.
MMTV-CreNLST and WAP-Cre delete Rbfl/fl in different cells within the 
mammary stem cell hierarchy. X-gal staining of mammary glands 
from WAP-Cre:ROSA26 females revealed high level of recombina-
tion during pregnancy and lactation (Figure 3A and ref. 51). In 
contrast, MMTV-CreNLST:ROSA26 mice exhibited high levels of 
recombination during pregnancy and lactation as well as during 
ductal morphogenesis and alveologenesis (Figure 3B).
Next, we sought to identify the cells within the mammary 
stem cell (MSC) hierarchy in which Rb is deleted by WAP-Cre 
versus MMTV-Cre. MSCs, luminal progenitors, and myoepithe-
lial progenitors were identified on the basis of expression of the 
cell surface markers CD24 (52) and either β1-integrin (CD29) or 
α6-integrin (CD49f; refs. 53, 54). A typical FACS profile of lin-
Figure 1
A lactation defect in WAP-Cre:Rbfl/fl:p107–/– mutant mice. (A) Shown are 2 
litters of 10-day old pups fed by a multiparous WAP-Cre:Rbfl/fl:p107–/– female 
(top, 4 pups) or control Rbfl/fl:p107–/– female (bottom, 6 pups). (B and C) 
Whole-mount staining of representative mammary glands from multiparous 
(third pregnancy) Rbfl/fl:p107–/– control (B) and WAP-Cre:Rbfl/fl:p107–/– (C) 
females at day 15 of lactation. Note more condensed lobuloalveoli in con-
trol relative to RbΔfl mammary gland. LA, lobuloalveoli; D, duct. (D–F) H&E 
staining of cross-sections through mammary glands from Rbfl/fl:p107–/– con-
trol (D) and WAP-Cre:Rbfl/fl:p107–/– (E and F) mice at day 15 of lactation. 
Arrows point to abnormal/involuting lobuloalveolar structures; asterisks 
mark abundant adipocyte tissue in RbΔfl lactating gland. A, alveolar lumen. 
Original magnification, ×50 (B and C); ×200 (D and E); ×400 (F).
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eage-depleted (Lin–) mammary epithelial cells sorted for CD24 
and CD49f expression is shown in Figure 3C. The presumptive 
MSCs or mammary repopulating units (MRU; CD24+CD49f+), 
myoepithelial progenitors (MYO; CD49f+), and colony-forming 
luminal progenitor cells (CFC; CD24+), as defined by Stingl et al. 
(54), are indicated. To test their differentiation potential, sorted 
cells were seeded onto collagen-1–coated plates, induced to dif-
ferentiate for 3 days, and immunostained with the luminal marker 
CK18, the stem/myoepithelial marker CK14, and the myoepithe-
lial marker SMA. The CD24–CD49f+ fraction differentiated into 
CK14+ and SMA+ cells; the CD24+CD49f– fraction differentiated 
into mostly CK14+CK18+ double-positive cells and was negative 
for SMA; and the CD24+CD49f+ fraction differentiated into SMA+, 
CK14+, and CK14+CK18+ cells (Figure 3C). Although the nature 
of the CK14+CK18+ cells is yet to be defined, these results are con-
sistent with the assignment of CD24–CD49f+ cells as myoepithe-
lial progenitors, CD24+CD49f– cells as luminal progenitors, and 
CD24+CD49f+ cells as MSCs or bipotent common progenitors.
To determine in which cells Rbfl/fl was excised, 6 mammary 
glands each (nos. 3, 4, and 5) from 4 multiparous MMTV-CreNLST: 
Rbfl/fl:p107–/– or multiparous WAP-Cre:Rbfl/fl:p107–/– mice approxi-
mately 6 months old were pooled (24 mammary glands), Lin– 
mammary epithelial cells were sorted as in Figure 3C, and DNA 
was extracted from each fraction. Cre-mediated recombination 
was then assessed by PCR with primers flanking exon 19, which 
can amplify 235-bp WT, 283-bp nonrecombined Rbfl, or 260-bp 
recombined RbΔfl alleles (Figure 3D and ref. 45). In WAP-Cre: 
Rbfl/fl:p107–/– mammary epithelium, the recombined RbΔfl allele 
was reproducibly observed only in the CD24+ luminal fraction, 
not in the CD24+CD49f+, CD49f+, or CD24–CD49f– fractions 
(Figure 3E). Densitometry analysis revealed that the percentage 
of RbΔfl relative to Rbfl was 15% in CD24+ cells, but undetectable 
in other cell fractions (Figure 3F). In contrast, in MMTV-CreNLST: 
Rbfl/fl:p107–/– mammary glands, recombination was observed pri-
marily in the CD24+CD49f+ MSC/bipotent cell fraction, with 
41% of the cells containing the recombined allele relative to Rbfl 
(Figure 3, E and F). Recombined RbΔfl was also observed in CD24+ 
and CD24–CD49f+ fractions upon loading more DNA and after 
a second round of PCR amplification, respectively (Figure 3, E 
and F, and Supplemental Figure 1, A and B; supplemental mate-
rial available online with this article; doi:10.1172/JCI41490DS1). 
Together, these results indicated that MMTV-Cre and WAP-Cre 
delete Rbfl in different cells within the MSC hierarchy, and this 
may underlie the different phenotypes of MMTV-Cre:Rbfl/fl:p107–/– 
and WAP-Cre:Rbfl/fl:p107–/– mice.
Deletion of Rb in mammary epithelium via MMTV-Cre, but not WAP-
Cre, expands MSCs/bipotent cells. To assess the effect of Rb deletion 
on the CD24+CD49f+ MSC/bipotent cell population, we compared 
the percentage of CD24+CD49f+ cells in MMTV-Cre:Rbfl/fl:p107–/– 
(n = 5) or WAP-Cre:Rbfl/fl:p107–/– (n = 5) mice relative to control 
littermates. The proportion of CD24+CD49f+ cells in WAP-Cre: 
Rbfl/fl:p107–/– relative to control animals was nearly identical, at a 
ratio of 0.98 (SD, 0.22; P = 0.44; Figure 3G). In contrast, the percent-
age of CD24+CD49f+ cells in MMTV-Cre:Rbfl/fl:p107–/– mice was on 
average 2.32-fold higher than controls (SD, 0.94; P = 0.034), ranging 
from 1.44- to 3.5-fold (Figure 3G). In addition, we seeded Lin– epi-
thelial cells from multiparous MMTV-Cre:Rbfl/fl:p107–/–, WAP-Cre: 
Rbfl/fl:p107–/–, and control mammary glands into ultra-low attach-
ment plates and measured the number of primary mammospheres 
that formed 2 weeks later. Mammosphere frequency increased by 
48% in MMTV-Cre:Rbfl/fl:p107–/– mammary glands and reduced by 
30% in WAP-Cre:Rbfl/fl:p107–/– glands relative to controls (Supple-
mental Figure 1C). Thus, MMTV-CreNLST, but not WAP-Cre, induced 
excision of Rbfl/fl in CD24+CD49f+ stem/bipotent cells, leading to a 
moderate yet consistent increase in this cell population.
Deletion of Rb in mammary epithelium via MMTV-Cre deleter lines 
induces mammary adenocarcinomas and adenosquamous carcinomas. 
Virtually all multiparous MMTV-Cre:Rbfl/fl females developed 
frank mammary tumors, with a mean latency of 18.4 months 
(Figure 4, A and B). As with premalignant lesions, tumor latency did 
Figure 2
MMTV-Cre:Rbfl/fl mice develop focal hyperplastic 
lesions. (A–D) Representative whole-mount carmine 
alum staining of MMTV-Cre:Rbfl/fl:p107+/– mutant (A 
and B) and control (C and D) mammary glands. Note 
lesions in the RbΔfl gland. Boxed regions in A and C 
are shown at higher magnification in B and D. A is a 
composite of 2 images. (E) H&E staining of a lesion 
from MMTV-Cre:Rbfl/fl:p107+/– mutant mammary 
gland, reproduced from 3 low-magnification micro-
graphs. (F–I) Representative analysis of nodules from 
8 independent mutant mice. Shown are TUNEL anal-
ysis for apoptosis (F) and IHC for PCNA (G), CK5 (H), 
and CK6 (I). Arrows point to representative stained 
cells. Original magnification, ×8 (A); ×10 (C); ×50 (B 
and D); ×100 (E); ×400 (F–I).
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Figure 3
Differential effects of MMTV-Cre and WAP-Cre on Rb deletion and stem/bipotent cell compartments. (A) Whole-mount X-gal staining of a 
lactating WAP-Cre:ROSA26 gland. (B) X-gal staining of developing endbuds and ducts during ductal morphogenesis (left, cross section; 
center, transverse section), and lobuloalveoli during lactation (right, whole-mount) in MMTV-CreNLST:ROSA26 mice. (C) CD24-CD49f FACS 
profile of multiparous Lin– normal mammary epithelium and gating used for cell sorting, and immunofluorescent staining for SMA, CK14, and 
CK18 on the indicated cell populations. DP, CD24+CD49f+ double positive. (D) Schematic representation of floxed Rb exon 19 and primers 
used to detect WT Rb, Rbfl, and recombined RbΔfl alleles. (E) PCR analysis of DNA extracted from pooled, sorted Lin– mammary epithelium 
from multiparous WAP-Cre:Rbfl/fl:p107–/– (n = 5) or MMTV-Cre:Rbfl/fl:p107–/– (n = 4) mice. Cells were gated as in C. Blot at bottom right shows 
overexposure after loading twice as much DNA, revealing low-level recombination in CD24+ cells. (F) Densitometry analysis of RbΔfl and Rbfl 
PCR fragments from E. DN, double negative. (G) Percentage of Lin–CD24+CD49f+ cells in multiparous WAP-Cre:Rbfl/fl:p107–/– (n = 5) and 
MMTV-Cre:Rbfl/fl:p107–/– (n = 5) mice relative to control. *P = 0.034, 1-tailed paired Student’s t test. Original magnification, ×63 (A); ×100 (B, 
left); ×400 (B, center, and C); ×50 (B, right).
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not appear to depend on p107, averaging 13, 18.7, and 19 months 
for MMTV-Cre:Rbfl/fl:p107+/+ (n = 2), MMTV-Cre:Rbfl/fl:p107–/– 
(n = 12), and MMTV-Cre:Rbfl/fl:p107+/– (n = 8) mice, respectively. 
Biallelic excision of exon 19 in these RbΔfl tumors was confirmed 
by complex PCR analysis (Figure 4C).
In contrast to the early focal 
lesions, the RbΔfl tumors were high-
ly heterogeneous (Figure 4, D–F, 
and Supplemental Figure 2). About 
40% of tumors were classified as 
adenosquamous carcinomas, and 
the rest represented various types 
of adenocarcinomas (Table 1 and 
Supplemental Figure 2). This 
tumor heterogeneity suggests that 
Rb inactivation may cooperate 
with different oncogenic path-
ways that transform the initially 
uniform hyperplastic lesions into 
distinct tumor subtypes. Macro-
scopic and microscopic examina-
tion of lungs from 14 RbΔfl tumor-
bearing mice revealed pulmonary 
lesions with histology similar to 
that of the primary tumor in 6 
mice (Figure 4, F and G).
We also generated a colony of 
Rbfl/fl mice with a second deleter 
strain, MMTV-CreD (55). With this 
line, we obtained MMTV-CreD: 
Rbfl/fl mice on p107+/– heterozygous, 
but not p107–/– homozygous, 
background. Of approximately 50 
mutant mice, 90% became mor-
bid by 8–10 months of age. Large 
mammary tumors developed in 1 
parous MMTV-CreD:Rbfl/fl:p107+/+ 
and 4 MMTV-CreD:Rbfl/fl:p107+/– 
females, with histology similar 
to those seen in MMTV-CreNLST: 
Rbfl/fl mice, yet with a shorter 
latency (average 10.5 months; data 
not shown). Moreover, 1 parous 
MMTV-CreD:Rbfl/+:p107+/– double-
heterozygous female developed a 
mammary tumor. PCR analysis 
revealed LOH at the Rb locus (Fig-
ure 4C, lane 4). In contrast, PCR 
analysis of 4 tumors from MMTV-
CreD:Rbfl/fl:p107+/– and MMTV-
CreNLST:Rbfl/fl:p107+/– females (i.e., 
heterozygous for p107+/–) revealed 
that the remaining WT p107 allele 
was maintained (data not shown).
RbΔfl tumors are transplantable. 
Flow cytometry analysis of Lin– 
cells from 4 different RbΔfl tumors 
revealed a 6.1-fold increase in 
the frequency of CD24+CD49f+ 
cells relative to control mammary 
epithelium (SD, 1.53; P < 0.05; Figure 4, H–J). To test for cell-
autonomous growth, we assessed the ability of RbΔfl tumor cells 
to form spheres in nonadherent cultures and xenografts in vivo. 
After seeding Lin– tumor cells on nonadherent plates in defined 
medium containing EGF and FGF (56–58), 8 of 11 tumors gave 
Figure 4
MMTV-Cre:Rbfl/fl and MMTV-Cre:Rbfl/fl:p107–/– mice develop transplantable mammary tumors. 
(A) Dissected MMTV-Cre:Rbfl/fl:p107–/– female with 2 large tumors in mammary gland nos. 4 and 5 
(arrows). (B) Tumor-free curve for a cohort of 22 RbΔfl mice (2 MMTV-Cre:Rbfl/fl:p107+/+, 12 MMTV-Cre: 
Rbfl/fl:p107–/– and 8 MMTV-Cre:Rbfl/fl:p107+/–) and 20 control (without MMTV-Cre) littermates. (C) Complex 
PCR analysis with the 3 primers. Lane 1, Rb+/+ mouse tail; lane 2, Rbfl/fl mouse tail; lane 3, MMTV-CreNLST: 
Rbfl/fl:p107–/– mammary tumor; lane 4, MMTV-CreD:Rbfl/+:p107+/– heterozygote mammary tumor, demon-
strating LOH at the Rb locus. Lanes were run on the same gel but were noncontiguous (white line). (D–G) 
H&E staining of representative RbΔfl tumors and pulmonary metastasis. (D) Tumor 2, adenosquamous 
carcinoma. (E) Tumor 4, solid adenocarcinoma with comedo patterns. (F) Tumor 9, adenocarcinoma with 
cystic changes. (G) Pulmonary metastasis in MMTV-Cre:Rbfl/fl:p107–/– mutant shown in F. Note glandu-
lar tumors with histology similar to the original tumor. Inset: low-magnification image of the pulmonary 
metastasis (right; normal lung tissue on left). (H and I) CD24-CD49f flow cytometry profiles of Lin– control 
mammary gland (H) and RbΔfl tumor (I). (J) Mean Lin–CD24+CD49f+ cells in RbΔfl mammary tumors (n = 4) 
relative to Lin– mammary epithelial cells from control littermates (n = 6). P < 0.01. (K–N) RbΔfl mam-
mary tumor cells were transplantable. (K) Secondary RbΔfl tumorspheres cultured for 2 weeks. (L) A 
Rag1–/– female mouse with secondary RbΔfl mammary tumors arising after transplantation of 10,000 and 
1,000 tumorsphere cells into the right and left, respectively, of mammary gland no. 4. (M) Primary, poorly 
differentiated adenocarcinoma. (N) Secondary tumor after transplantation of tumorsphere cells derived 
from the tumor in M. Original magnification, ×200 (D–F); ×400 (G, M, and N); ×100 (G, inset); ×20 (K).
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rise to tumorsphere cultures that survived for 3 or more passages 
(Figure 4K). Upon transplantation into mammary glands of recipi-
ent Rag1–/– mice, 8 independent RbΔfl tumorspheres gave rise to sec-
ondary tumors (Figure 4L) that exhibited histology similar to that 
of the primary tumors from which they were derived (Figure 4, M 
and N). Thus, at least some RbΔfl tumor cells can disseminate new 
tumors independently of tumor-associated stroma.
RbΔfl tumors express basal cytokeratins, but not ERα. To begin to 
classify the RbΔfl tumors into subtypes, we stained histological 
sections for the myoepithelial/basal cell markers CK5 and CK14 
as well as ERα. Of 12 RbΔfl tumors, 8 expressed CK5 in tumor 
epithelium or squamous areas (Figure 5, A–C, and Table 1). We 
also observed that 2 tumors were negative for CK5 in the epithe-
lium compartment, but positive in keratinized areas (Figure 5D). 
CK14 was expressed at different levels in all tumors except for 
tumors 4 and 10 (Figure 5, E–H, and Table 1). Importantly, with 
the exception of the papillary adenomyoepithelioma (tumor 11), 
all RbΔfl tumors were negative for, or expressed very low levels of 
(tumor 4), ERα (Figure 5, I–L, and Table 1). Consistent with its 
role in epidermal transdifferentiation (59), we observed variable 
levels of β-catenin expression at the cell membrane in nodular 
areas of tumors (Figure 5, N–P), but almost exclusive nuclear 
staining in cells surrounding keratinized areas in adenosqua-
mous tumors (Figure 5M, arrows).
RbΔfl mammary tumors cluster with T121- and Tag-induced tumors with fea-
tures of luminal-B or basal-like breast cancer. To further classify the RbΔfl 
mammary tumors, we subjected 9 tumor biopsies to microarray-
based gene expression analysis. Previous gene expression profiling 
of 13 different mouse models of breast cancer, using 866 informa-
tive genes, revealed that tumors induced by SV40 Tag (C3-Tag and 
WAP-Tag) clustered with human basal-like breast cancer, whereas 
tumors induced by a truncated T antigen (WAP-T121), which binds 
Rb family but not p53, clustered primarily with luminal-B (9).
Figure 6A shows an overview of the complete 866-gene cluster 
diagram for the RbΔfl tumors and the 13 mouse models. Selected 
groups of genes are shown in detail: the luminal gene cluster 
(Figure 6B), the CK5 basal-like gene cluster in the mouse (Figure 6C), 
the CK14 basal-like gene cluster in the mouse (Figure 6D), 
proliferation-associated genes (Figure 6E), and genes associ-
ated with EMT (Figure 6F). In addition, Figure 6G highlights 
genes on the Rb pathway: E2Fs, G1-cyclins, and CDK inhibitors, 
including p16Ink4a.
We found 6 RbΔfl tumors to cluster with either Tag (tumors 3 and 4) 
or T121 (tumors 1, 5, 6, and 9), which were previously classified as 
basal-like/TNT and luminal-B–like breast tumors, respectively (9). 
Tumors 2 and 11 clustered with squamous tumors induced by 
DMBA and also expressed markers associated with basal-like/TNTs. 
Tumor 10 clustered with NEU+ tumors. The basal-like tumors (nos. 
2, 3, 4, and 11), but not luminal-B or NEU+ tumors (nos. 1, 5, 6, 9, 
and 10), expressed high levels of EMT associated genes including 
snail homolog 1, TIMP1, and Rho GTPase activator 22 (Figure 6F).
Among genes on the Rb pathway (Figure 6G), cyclin D1 was 
expressed at low levels in most tumors, with the exception of 
tumor 11, whereas cyclin D2 was expressed at levels comparable to 
or slightly higher than (tumors 2 and 4) those of normal mam-
mary glands. Consistent with this, IHC analysis revealed high 
expression of nuclear cyclin D1 in glandular tumor cells only in 
tumor 11, whereas nuclear cyclin D2 was detected in epithelium, 
stroma, or keratinized areas in 10 of 11 RbΔfl mammary tumors 
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Array CGH analysis revealed a tendency toward more gains and/or 
losses in the Rb-deficient Tag/TNTs (tumors 3 and 4) compared 
with the 7 other Rb tumors (Supplemental Figure 4A and data not 
shown). Major losses and gains were found in chromosome 15 in 
tumors 3 and 4, but not in tumors 1, 5, 6, and 9 (Supplemental 
Figure 4B) or in tumors 2, 10, or 11 (data not shown). This region 
in chromosome 15 showed conservation of synteny with human 
chromosomes 5p13 and 8q22, which frequently undergo chromo-
somal gains in human breast cancer (60). Thus, these RbΔfl tumors 
could be divided into 2 major groups: T121/luminal-B–like (nos. 
1, 5, 6, and 9) and basal-like (nos. 2, 3, 4, and 11). The basal-like 
group could be further divided into 2 subgroups: Tag-like (nos. 3 
and 4) and DMBA-like (nos. 2 and 11).
Tag/basal-like, but not T121/luminal-B–like, RbΔfl mammary tumors 
express a human RB1-LOH proliferation gene signature. Analysis of 
human breast tumors with LOH at the RB1 locus led to the 
generation of a RB1-specific proliferation signature (29). We 
created an average expression value for the human RB1-LOH 
signature and compared it with the levels of expression in RbΔfl 
mammary tumors. The top 2 samples were the Rb-deficient 
Tag/basal-like tumors 3 and 4, with values of 0.37 and 0.47, 
respectively. The average value for T121/luminal-B–like tumors 
(nos. 1, 5, 6, and 9) was 0.13 (0.04, 0.22, 0.09, and 0.17, respec-
tively). Thus, the RbΔfl tumors that share the human RB1-LOH 
proliferation signature are tumors 3 and 4, which cluster with 
Tag/basal-like carcinoma.
Tag/basal-like RbΔfl tumors express 
high levels of p53. To begin to 
understand the basis for tumor 
heterogeneity downstream of Rb, 
we investigated the status of p53. 
Remarkably, Tag/basal-like RbΔfl 
tumors exhibited high, near-uni-
form expression of nuclear p53, 
whereas DMBA-like RbΔfl tumors 
expressed nuclear p53 in a small 
fraction of the cells (Figure 7A, 
top, and Supplemental Figure 5). 
In contrast, RbΔfl luminal-B or 
NEU+ tumors did not express 
detectable levels of p53 (Figure 7A, 
bottom, and Supplemental 
Figure 5). Analysis of additional 
RbΔfl tumors identified 3 more 
with high expression of p53: a 
solid adenocarcinoma (tumor 
48; Supplemental Figure 5), 
and 2 spindle-cell/EMT tumors 
(tumors 18 and 30; Figure 8, A 
and B, and see below).
The RbΔf l basal-like tumors 
exhibited higher rates of cell prolif-
eration and similar levels of apop-
tosis compared with the luminal-
like tumors (Figure 7, B and C), 
which suggested that they con-
tained mutant p53 (see below). In 
addition, IHC analysis for p16Ink4a 
identified small pockets of positive 
cells in RbΔfl basal-like tumors, but 
not luminal-B–like tumors (Figure 7D). The relatively low IHC sig-
nal was likely related to the low sensitivity of anti-mouse p16Ink4a 
antibodies. Indeed, at the RNA level, p16Ink4a was highly expressed 
in the RbΔfl basal-like tumors, but not other tumors (Figure 6G). 
This elevated p16Ink4a expression is consistent with its high expres-
sion in RB1-negative human basal-like breast cancer (28–30).
RbΔfl spindle cell tumors express mutant p53 and markers of EMT. As 
noted above, tumors 18 and 30 exhibited spindle-cell morphol-
ogy (Figure 8, A and B). These tumors expressed high levels of 
p53 as well as the EMT-associated markers N-cadherin and des-
min (Figure 8B, data not shown, and ref. 61). They readily grew as 
monolayer cultures and were highly aggressive; transplantation 
of 1,000 monolayer cells into the mammary glands of recipient 
mice gave rise to large tumors within 2–3 weeks that retained the 
same histology and marker expression as the parental tumors 
(Figure 8B). Consistent with their mesenchymal characteris-
tics, flow cytometry analysis revealed that these tumors lost the 
CD24+ luminal marker, exhibiting a high CD49f+ to CD24+ ratio 
(Figure 8D). EMT tumors with spindle-cell morphology were 
previously described in several mouse models of breast cancer, 
including some rare mammary tumors with null mutations in 
p53 (62). In humans, EMT tumors in breast cancer have been rec-
ognized within the larger TNT group that includes claudin-low 
and metaplastic breast cancer (9–14). Thus, some RbΔfl mammary 
tumors express nuclear p53, are highly aggressive, and exhibit 
spindle-cell/EMT morphology.
Figure 5
Most RbΔfl mammary tumors express variable levels of basal cytokeratins, but not ERα. Representative 
IHC of tumors 2, 4, 9, and 11 for CK5 (A–D), CK14 (E–H), ERα (I–L), and β-catenin (M–P). Inset in D 
shows CK5 expression in squamous area. Arrows in M mark cells surrounding keratinized area (Ker) 
with nuclear localized β-catenin. Original magnification, ×400 (A–P and D, inset).
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Figure 6
RbΔfl mammary tumors cluster with DMBA and Tag-induced basal-like or T121-induced luminal-B–like breast tumors. (A) Overview of expression 
of 866 reference genes in tumors from RbΔfl and 13 mouse models of breast cancer. Colored regions at left correspond to the regions shown in 
B–F. (B) Selected genes representing the luminal gene cluster. (C) CK5 basal-like gene cluster. (D) CK14 basal-like gene cluster. (E) Prolifera-
tion-associated gene cluster. (F) EMT gene cluster. (G) Subset of proliferation-associated genes. Asterisks at the top mark the 9 RbΔfl tumors; 
tumor models that clustered with RbΔfl tumors are highlighted at the bottom. DMBA, 7,12-dimethylbenz[a]-anthracene.
research article
3304	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 120   Number 9   September 2010
Tag/basal-like and EMT RbΔfl tumors contain p53 mutations. To deter-
mine whether high p53 expression in these tumors was caused 
by mutations in p53, which stabilizes the protein (63, 64), we 
sequenced exons 2–9 of p53 in tumors 3, 4, 18, and 30. We identified 
missense mutations K129M, H165R, C138R, and C138R, respec-
tively, in the DNA-binding domain of these tumors (Figure 9). 
These amino acids were conserved in human p53 (K132, H168, 
C141, and C141, respectively) and are frequently mutated in human 
cancer (65, 66). Tumors 3 and 4 only harbored the mutant allele, 
whereas tumors 18 and 30 contained both the WT and mutant 
alleles, which suggests that C138R acts as dominant negative.
Combined deletion of Rb and p53 in mammary epithelium via MMTV-
Cre induces aggressive spindle cell/EMT tumors. The above results 
suggest that p53 status dictates whether the focal hyperplas-
tic lesions in MMTV-Cre:Rbfl/fl mice develop into luminal-B or 
basal-like/EMT tumors. We predicted that combined deletions 
of Rb and p53 would lead to uniform basal-like or EMT tumors 
at the expense of luminal-B. To test this notion, we crossed the 
MMTV-Cre:Rbfl/fl mice with floxed p53 (p53fl/fl) mice (67). Mam-
mary-specific deletion of p53fl/fl leads to ERα-positive and -nega-
tive tumors with a latency of more than 11 months (68). MMTV-
Cre:Rbfl/fl:p53fl/fl double-mutant mice were viable and fertile, yet 
nearly all developed lethal lymphomas within 2–6 months. To 
circumvent this, we purified Lin– mammary epithelial cells from 
2 independent MMTV-Cre:Rbfl/fl:p53fl/fl mice and transplanted 
10,000 cells each into the mammary glands of 4- to 5-week-old 
NOD/SCID mice. Tumors developed with an average latency of 
126 days (6 tumors in 12 injections; 50%) and 58 days (10 tumors 
in 24 injections; 42%). Given that the mammary epithelium 
was derived from 76- and 119-day-old mice, the total latency 
for tumor formation was 202 and 177 days, an average of 190 
days (i.e., about 6.5 months). PCR analysis confirmed deletion 
of Rb and p53 (Figure 10A). Analysis of 10 independent tumors 
revealed similar mesenchymal histology, characterized by spin-
dle-shaped cells with abundant pink cytoplasm (Figure 10B). 
Some regions contained epithelial components surrounded by 
mesenchymal cells (Figure 10C), consistent with EMT. Indeed, 
expression of CK8 (Figure 10E) was restricted to epithelial cells 
within tumors, whereas mesenchymal areas expressed the EMT 
markers desmin and N-cadherin (Figure 10, F and G) and were 
indistinguishable from the Rb/p53 mesenchymal tumors derived 
from MMTV-Cre:Rbfl/fl mice (Figure 8).
Reintroduction of Rb into aggressive RbΔfl/p53Δfl EMT tumor cells sup-
presses their growth. Many tumors are dependent on (i.e., addicted to) 
the continuous expression of oncogenes that drive them (reviewed 
in refs. 69, 70). Although introduction of constitutively activated, 
unphosphorylatable pRb alleles often suppress cell proliferation, 
WT pRb seems to inhibit only certain cells, likely with low levels of 
cyclins (71–75). To test whether growth of RbΔfl/p53Δfl tumor cells is 
dependent on the continuous absence of pRb, we transduced WT 
Rb via a retrovirus vector that also encodes GFP. Expression of pRb 
was confirmed by immunofluorescent staining (data not shown). 
GFP+ cells transduced with Rb (pMXIE-GFP-Rb) or vector alone 
(pMXIE-GFP) were sorted, and 500 GFP+ cells were seeded onto 
96-well plates. After 1 week, MTT assays revealed approximately 
5-fold inhibition of cell growth in Rb-transduced cultures relative 
to controls (Figure 11A). The GFP-sorted cells were also trans-
planted into mammary glands of 4- to 5-week-old NOD/SCID 
mice. Mice transplanted with 1,000 control tumor cells (empty 
vector) developed large tumors within 2–3 weeks (12 of 12; 
Figure 11B). In contrast, mice transplanted with Rb-GFP+ tumor 
cells did not develop tumors (0 of 12; Figure 11C). Thus, despite 
their aggressive nature, the RbΔfl/p53Δfl mammary tumors were 
addicted to continual absence of Rb and readily inhibited when 
reconstituted with this tumor suppressor.
Discussion
We describe the consequences of Rb deletion in the mammary epi-
thelium and delineate several stages in tumor initiation and pro-
gression leading to distinct breast cancer subtypes (Figure 10H). 
First, loss of Rb in stem/bipotent progenitor cells expands 
this cell population. As these cells attempt to exit the cell cycle 
and differentiate into single-lineage (luminal or myoepithe-
lial) progenitors, they undergo apoptotic death, which restricts 
their growth. Second, in cooperation with a limited number of 
oncogenic events (M2), some RbΔfl epithelial cells continue to 
proliferate to form focal acinar hyperplasia with propensity to 
squamous transdifferentiation. These lesions exhibit high levels 
Figure 7
Tag/basal-like RbΔfl tumors express high levels of nuclear p53. (A) High nuclear p53 expression in RbΔfl basal-like, but not luminal-B–like, tumors. 
(B) Representative IHC for the proliferation marker Ki67. (C) Representative TUNEL analysis. (D) IHC for p16Ink4a showing a cluster of positive 
cells. Original magnification, ×400 (A–C); ×200 (D).
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of both cell proliferation and apoptosis. Third, additional muta-
tions, which increase cell proliferation and/or inhibit apoptosis 
or differentiation, further transform these hyperplastic lesions 
into distinct tumor subtypes. We showed here that mutations 
in p53 induced basal-like or EMT tumors. We note that whereas 
the basal-like tumors were defined by microarray cluster analy-
sis, the EMT tumors were identified by their spindle-cell mor-
phology and expression of mesenchymal markers. Of interest, 
knockdown of RB1 in MCF7 breast cancer cells induces EMT 
(76). However, our results demonstrated that Rb loss also 
induced luminal-B–like as well as HER2+-like tumors that did 
not express EMT markers. Thus, other mutations, which are yet 
to be defined, cooperate with Rb loss to induce luminal-B–like 
tumors or other subtypes. Remarkably, combined mutations in 
Rb and p53 led to uniform types of EMT tumors at the expense 
of all others, which suggests that the timing of tumor suppres-
sor inactivation may also dictate tumor subtype.
Why does deletion of Rb in mammary epithelium lead to mam-
mary tumors, whereas Rb–/– mammary epithelial cells from embry-
onic placodes transplanted into recipient mice do not (39)? We 
suggest the discrepancy may be due to dependency on pregnan-
cy for tumor formation in Rb-deficient mammary epithelium. 
Indeed, we found that mammary tumors developed only in par-
ous MMTV-Cre:Rbfl/fl female mice. In contrast, the transplanted 
embryonic Rb–/– mammary epithelial cells were not taken through 
pregnancy (39). Notably, mammary tumors developed from trans-
planted MMTV-Cre:Rbfl/fl:p53fl/fl epithelium without pregnancy, 
indicating that loss of p53 bypassed this requirement.
The effect of Rb deletion was critically dependent on the 
cell within the mammary epithelial hierarchy in which it was 
disrupted: deletion of Rb via WAP-Cre led to minor lactation 
defects but not tumor formation, whereas deletion via 2 dif-
ferent MMTV-Cre lines led to mammary tumors. We showed 
that MMTV-Cre induced efficient Rb deletion primarily in 
CD24+CD49f+ stem/bipotent progenitors, whereas WAP-Cre 
induced deletion in CD24+ luminal progenitors. WAP-Cre is 
expressed in parity-identified multipotent alveolar stem cells 
(43, 77). Some low level of recombination within the stem cell/
bipotent cell compartment may occur in WAP-Cre:Rbfl/fl mam-
mary glands, but this is masked and greatly underrepresented 
relative to CD24+ cells, in which WAP-Cre is most abundantly 
expressed (78). The fact that tumors arose in MMTV-Cre:Rbfl/fl 
mice, but not WAP-Cre:Rbfl/fl mice, indicates that even if some 
low level of Rb deletion occurs in parity-identified multipotent 
epithelial cells, these cells are inherently different or exposed to 
a different microenvironment that diminishes their susceptibil-
ity to neoplastic transformation compared with ductal stem/
bipotent progenitors.
Figure 8
Spindle-cell RbΔfl tumors express 
nuclear p53 and markers of EMT. 
(A) Histology staining of primary 
EMT tumor 30. (B) Histology stain-
ing and IHC for p53, desmin, and 
N-cadherin of primary EMT tumor 
18 and a secondary tumor deriva-
tive. (C) Lack of desmin and 
N-cadherin expression in MMTV-
neu tumor. (D) Representative 
flow cytometry profile of RbΔfl EMT 
tumors demonstrating a high CD49f 
to CD24 ratio. Original magnifica-
tion, ×400.
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Given the high frequency with which Rb and p53 are lost in TNT/
basal-like breast cancer, and our results demonstrating that muta-
tions in p53 cooperated with Rb loss to induce aggressive EMT 
tumors, these tumor suppressor pathways may be ideal therapeu-
tic targets for TNTs. Importantly, we showed that transduction of 
WT pRb completely abolished growth of RbΔfl/p53Δfl TNTs. Thus, 
these tumors were addicted to Rb loss; drugs that mimic pRb func-
tion (79), perhaps in combination with drugs that activate mutant 
p53 (80), may therefore suppress the growth these tumors. The 
mouse models described here as well as 2 other models of TNTs — 
combined deletion of Brca1 and p53 (81) and overexpression of the 
Met receptor tyrosine kinase (82) — provide invaluable preclini-
cal platforms to identify and assess potential therapeutics for this 
aggressive breast cancer subtype (83).
Methods
Mouse genotyping and genetic analysis. All procedures were done in accor-
dance with the current Canadian Animal Care Council guide for the care 
and use of laboratory animals and were approved by the Toronto General 
Research Institute Animal Research Committee. MMTV-Cre:Rbfl/fl, MMTV-
Cre:Rbfl/fl:p107–/–, and WAP-Cre:Rbfl/fl:p107–/– mice were on mixed genetic 
backgrounds. Rbfl/fl:p107–/– mice were provided by R. Bremner (Toronto 
Western Hospital, Toronto, Ontario, Canada). MMTV-CreD was purchased 
from Jackson Laboratory. p53fl/fl mice were obtained from the NCI Mouse 
Repository. Genotyping was based on published primers and confirmed in 
tumor-bearing animals by second rounds of PCR reactions. Recombined 
Rb alleles were resolved on 3% NuSieve gel.
Whole mount and X-gal staining. Mammary glands were fixed in 4% PFA, 
dehydrated in 100% ethanol, and stained with 0.2% carmine alum plus 0.5% 
Figure 10
MMTV-Cre:Rbfl/fl:p53fl/fl double mutant mice develop spindle cell/EMT tumors. (A) PCR analysis of tail from MMTV-Cre:Rbfl/fl:p53fl/fl mice and 
tumor DNA for recombined Rb and p53 alleles or Cre. (B and C) Histology staining of Rb/p53 tumor showing spindle/mesenchymal and epithelial 
components (C). (D–G) Representative IHC staining for the indicated antibodies. e, epithelium. (H) Schematic model for tumor formation after 
Rb deletion in the mammary epithelium. See Discussion for details. Original magnification, ×400.
Figure 9
Identification of p53 mutations in Tag/basal-like and EMT 
RbΔfl tumors. (A) DNA sequencing reaction around K129 in 
control DNA (left) and tumor 3 (right). (B) Schematic rep-
resentation of human p53 and relative location (asterisks) 
of mutations identified in mouse RbΔfl tumors: Tag/basal-
like tumor 3, K129M (human, K132M); Tag/basal-like 
tumor 4, H165R (human, H168R); EMT tumors 18 and 30, 
C138R (human, C141R). TAD, N-terminal transactivation 
domain; PRR, proline-rich region; TET, tetramerization 
domain, CT, C terminus.
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aluminum potassium sulfate. Glands were destained in 70% ethanol plus 2% 
HCl, 90% ethanol, and 100% ethanol at 1 hour each, immersed in Toluene for 
4 hours, and stored in methyl salicylate. Whole-mount X-gal staining was as 
described previously (74). Images were obtained via Leica stereomicroscope.
IHC and TUNEL analysis. IHC on 4-μm sections was performed with 
a Vector ABC kit (PK6100). Antibodies were cyclin D1 (Neo Markers, 
MS-210-P1, catalog no. sc20044; Santa Cruz Biotechnology Inc.), cyclin D2 
(catalog no. sc593; Santa Cruz Biotechnology Inc.) ER (catalog no. sc542; 
Santa Cruz Biotechnology Inc.), CK6 (catalog no. PRB 169P; Covance), 
CK14 (catalog no. E2624; Panomics), β-catenin (catalog no. 610153; BD 
Biosciences), p53 (FL-393; catalog no. sc-6243; Santa Cruz Biotechnology 
Inc.), Ki67 (catalog no. CRM325, clone SP6; Biocare Medical), Desmin 
(catalog no. D33; DAKO), and Rb (catalog no. 554136; BD) at 1:200 dilu-
tions. PCNA monoclonal antibody (catalog no. P8825; Sigma-Aldrich) was 
used at 1:400 dilution, CK5 at 1:500 (catalog no. PRB-160P; Covance), and 
N-cadherin at 1:600 (catalog no. NB200-592; Novus Biologicals). Second-
ary biotinylated anti-mouse or anti-rabbit antibodies (Vector) were used at 
1:200 dilution. Sections were counterstained with methyl green. TUNEL 
analysis was performed as described previously (74).
Mammary epithelial cells, flow cytometry analysis, and cell sorting. Enrich-
ment for mammary epithelial cells, flow cytometry, and cell sorting were 
performed as described previously (58) using PE-CY5-CD49f (catalog no. 
555736; BD Biosciences — Pharmingen), CD24-FITC (catalog no. 553261; 
BD Biosciences — Pharmingen), and FACSCalibur flow cytometer or 
FACSAria-13 color Cell Sorter (BD) at 30 psi.
In vitro differentiation and immunocytostaining. Sorted cells were seeded 
onto collagen-1–coated coverslips (catalog no. 354089; VWR, BD Biosci-
ences) in growth media (DMEM/F-12, 10% FBS, 5 μg/ml insulin, 1 μg/ml 
hydrocortisone, 5 ng/ml EGF, and penicillin/streptomycin) for 3 days. Dif-
ferentiation was induced for 3 additional days in DMEM/F-12 containing 
5 μg/ml insulin, 1 μg/ml hydrocortisone, 3 μg/ml prolactin, and penicillin/
streptomycin. Cells were stained as described previously (58) using rabbit 
anti-SMA (1:200 dilution; catalog no. 600-531; Novus Biologics), mouse 
anti-K18 (1:200 dilution; catalog no. RDI-PR061028; Fitzgerald), and rab-
bit anti-CK14 (1:200 dilution; catalog no. E2624; Panomics). Secondary 
antibodies were goat anti-rabbit Alexa Fluor 488 (green, 1:200 dilution; 
catalog no. A11008; Invitrogen) or goat anti-mouse Alexa Fluor 568 (red, 
1:200 dilution; catalog no. A11004; Invitrogen). Nuclei were visualized with 
DAPI (catalog no. D9542; Sigma-Aldrich) and viewed under Zeiss Axioskop 
2 fluorescent microscope.
Tumorsphere and mammosphere culture and transplantation. Lin– tumor cell 
suspensions were seeded onto ultra-low attachment plates (catalog no. 
3471; Corning Costar) as described previously (58). For transplantation, 
primary tumorspheres were dissociated, resuspended in 10 μl media, mixed 
at a 1:1 ratio with 10 μl Matrigel (BD Bioscience) on ice, and injected into 
no. 4 mammary glands of immunocompromised Rag1–/– or NOD/SCID 
mice. Lin– mammary epithelial cells were seeded at 5,000 cells/well onto 
96-well plates, and mammospheres were counted 2 weeks later.
Retrovirus infection. Plasmids pMXIE, pMXIE-WTRb, and pMXIE-
RbΔK11 (provided by R. Bremner) as well as p-Helper and p-VSVG were 
purified by endotoxin-free QIAGEN Maxi kit, transfected into Phoenix 
Eco packaging cells using TransIT-LT1 transfection reagent (product nos. 
MIR 2300, 2305, and 2306; Mirus Bio), and harvested after 40–68 hours. 
Rb/p53 tumor cells maintained in DMEM with 10% FBS were infected 
with viral supernatants at 1:10 dilution with 8 μg/ml polybrene. After 
48 hours, cells were immunostained for Rb or sorted for GFP, and either 
replated in 96-well plates (500 cells/well) for MTT analysis or transplanted 
into mammary glands of NOD/SCID mice.
Microarray analysis and array CGH analysis. Tumors were snap-frozen in 
liquid nitrogen. RNA and DNA were purified from the same biopsies using 
RNeasy and DNAeasy kits from Qiagen. RNA was labeled with Cy5 and 
used for microarray analysis as described previously (9). The dataset was 
deposited in the GEO database (http://www.ncbi.nlm.nih.gov/geo/; acces-
sion no. GSE14457). DNA was labeled according to the direct incorpora-
tion method of Agilent, hybridized to Agilent 244k CGH arrays (model 
G4415A), and scanned (model G2505B) at a resolution of 5 μm. Tail DNA 
from 4 Rb mutant female mice was used as reference.
p53 sequencing. Tumors 3 and 4 were sequenced from biopsies, tumor 
18 from a derived cell line, and tumor 30 from both biopsy and a 
derived cell line. Primers were as follows: exons 2–4 forward, 5′-GCAG-
GATCCACAATCTCTTCTCTCTACAG-3′; exons 2–4 reverse, 5′-CCG-
GAATTCAAAGGTCACACGAAAGACAAC-3′; exons 5–6 forward, 5′-
TAAGGATCCTTAGTTCCCCACCTTGACACC-3′; exons 5–6 reverse, 
5′-TCCGAATTCTCTAGGCTGGAGTCAACTGTC-3′; exons 7–9 forward, 
5′-TAAGGATCCTTCACCTGGATCCTGTGTCTTC-3′; exons 7–9 reverse, 
5′-TCCGAATTCAATGGGTACAGCTTGTCTCTGG-3′. PCR amplifica-
tion reactions were purified on Qiagen PCR purification columns and 
subjected to high-quality capillary-based fluorescent sequencing on 
dual ABI 3730XL instruments at the Hospital for Sick Children TCAG 
Sequencing Facility. Identified mutations were verified by 2 additional 
PCR reactions/sequencing.
Statistics. Average across independent experiments is presented as mean 
of each experiment relative to control, which was set as 1 or 100%, and ana-
lyzed by 2-tailed Student’s t test (except 1-tailed analysis in Figure 3G). A 
P value of 0.05 or less was considered statistically significant.
Figure 11
Aggressive spindle cell/EMT RbΔfl tumors are addicted to Rb loss. (A) 
Retrovirally mediated transduction of Rb into mesenchymal RbΔfl tumor 
cells inhibited cell proliferation in vitro. RbΔfl tumor cells were infected 
with the indicated virus, sorted for GFP+ and GFP– cells, seeded at 500 
cells per well, and analyzed by MTT assay for cell proliferation 1 week 
later. Shown is mean ± SD from 3 independent experiments relative 
to GFP– cells. P = 0.019 for suppression by Rb. (B and C) Retrovirally 
mediated transduction of Rb into EMT RbΔfl tumor cells inhibited tumor 
formation. RbΔfl tumor cells were infected with GFP or Rb-GFP viruses, 
sorted, and 1,000 GFP+ cells were transplanted into no. 4 mammary 
glands of NOD/SCID mice. Tumors were detected 2 weeks later and 
scored after 3 weeks. (B) A dissected mouse carrying tumors (T) after 
transplantation of GFP+ cells. (C) Whole-mount staining revealing 
endogenous mammary epithelium, but no tumor, after transplanting 
Rb-GFP+ cells. Arrowhead points to site of injection. Original magnifi-
cation, ×10. Scale bar: 1 cm (B).
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